{"associatedParty":[{"classifier":[{"coding":[{"code":"INDUSTRY","display":"INDUSTRY","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-AgencyClass"}]}],"name":"Alebund Pharmaceuticals","role":{"coding":[{"code":"sponsor","display":"Sponsor","system":"http://hl7.org/fhir/research-study-party-role"}]}},{"classifier":[{"coding":[{"code":"INDUSTRY","display":"INDUSTRY","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-AgencyClass"}]}],"name":"Alebund Pty Ltd","role":{"coding":[{"code":"lead-sponsor","display":"Lead sponsor","system":"http://hl7.org/fhir/research-study-party-role"}]}},{"name":"Sam Francis, Doctor","party":{"display":"Nucleus Network"},"role":{"coding":[{"code":"primary-investigator","display":"Principal investigator","system":"http://hl7.org/fhir/research-study-party-role"}]}}],"classifier":[{"text":"Has Results: False"},{"text":"Oversight Classifier: oversightHasDmc True"},{"text":"Oversight Classifier: isFdaRegulatedDrug False"},{"text":"Oversight Classifier: isFdaRegulatedDevice False"}],"comparisonGroup":[{"eligibility":{"display":"AP303","reference":"#NCT05503693-comparison-group-0","type":"Group"}},{"eligibility":{"display":"Placebo","reference":"#NCT05503693-comparison-group-1","type":"Group"}}],"condition":[{"text":"Healthy Subjects"}],"contained":[{"description":"AP303 tablet","id":"NCT05503693-drug------ap303-50-g","name":"NCT05503693_drug______ap303_50_g","resourceType":"EvidenceVariable","status":"active","title":"AP303 50 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"AP303 tablet","id":"NCT05503693-drug------ap303-150-g","name":"NCT05503693_drug______ap303_150_g","resourceType":"EvidenceVariable","status":"active","title":"AP303 150 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"AP303 tablet","id":"NCT05503693-drug------ap303-300-g","name":"NCT05503693_drug______ap303_300_g","resourceType":"EvidenceVariable","status":"active","title":"AP303 300 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"AP303 tablet","id":"NCT05503693-drug------ap303-600-g","name":"NCT05503693_drug______ap303_600_g","resourceType":"EvidenceVariable","status":"active","title":"AP303 600 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"Placebo tablet","id":"NCT05503693-drug------placebo-50-g","name":"NCT05503693_drug______placebo_50_g","resourceType":"EvidenceVariable","status":"active","title":"Placebo 50 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"Placebo tablet","id":"NCT05503693-drug------placebo-150-g","name":"NCT05503693_drug______placebo_150_g","resourceType":"EvidenceVariable","status":"active","title":"Placebo 150 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"Placebo tablet","id":"NCT05503693-drug------placebo-300-g","name":"NCT05503693_drug______placebo_300_g","resourceType":"EvidenceVariable","status":"active","title":"Placebo 300 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"description":"Placebo tablet","id":"NCT05503693-drug------placebo-600-g","name":"NCT05503693_drug______placebo_600_g","resourceType":"EvidenceVariable","status":"active","title":"Placebo 600 μg","useContext":[{"code":{"code":"interventionType","display":"Intervention Type for ClinicalTrials.gov","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionType"},"valueCodeableConcept":{"text":"DRUG"}}]},{"characteristic":[{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: AP303 50 μg","reference":"#NCT05503693-drug------ap303-50-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: AP303 150 μg","reference":"#NCT05503693-drug------ap303-150-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: AP303 300 μg","reference":"#NCT05503693-drug------ap303-300-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: AP303 600 μg","reference":"#NCT05503693-drug------ap303-600-g","type":"EvidenceVariable"}}],"combinationMethod":"all-of","description":"AP303","id":"NCT05503693-comparison-group-0","identifier":[{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-comparison-group-0"}],"membership":"conceptual","resourceType":"Group","status":"active","title":"NCT05503693 Comparison Group: AP303","useContext":[{"code":{"code":"ArmGroupType","display":"Arm Group Type","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure"},"valueCodeableConcept":{"coding":[{"code":"EXPERIMENTAL","display":"Experimental","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType"}]}}]},{"characteristic":[{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: Placebo 50 μg","reference":"#NCT05503693-drug------placebo-50-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: Placebo 150 μg","reference":"#NCT05503693-drug------placebo-150-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: Placebo 300 μg","reference":"#NCT05503693-drug------placebo-300-g","type":"EvidenceVariable"}},{"code":{"text":"Exposed to"},"exclude":false,"valueReference":{"display":"Drug: Placebo 600 μg","reference":"#NCT05503693-drug------placebo-600-g","type":"EvidenceVariable"}}],"combinationMethod":"all-of","description":"Placebo","id":"NCT05503693-comparison-group-1","identifier":[{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-comparison-group-1"}],"membership":"conceptual","resourceType":"Group","status":"active","title":"NCT05503693 Comparison Group: Placebo","useContext":[{"code":{"code":"ArmGroupType","display":"Arm Group Type","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure"},"valueCodeableConcept":{"coding":[{"code":"PLACEBO_COMPARATOR","display":"Placebo Comparator","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-ArmGroupType"}]}}]},{"address":{"city":"Melbourne","country":"Australia","postalCode":"3004","state":"Victoria"},"id":"NCT05503693-Location-0","name":"Nucleus Network Pty Ltd","position":{"latitude":-37.814,"longitude":144.96332},"resourceType":"Location"}],"description":"The study will consist of 2 parts: Part A is a single ascending doses (SAD) phase enrolling a total of 4 cohorts of healthy subjects; Part B is a multiple ascending doses (MAD) phase enrolling 3 cohorts of healthy subjects. One cohort of Part A will receive AP303 under both fasted and fed conditions to investigate the effect of food.","descriptionSummary":"This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.","id":"example-ctgov-study-record","identifier":[{"assigner":{"display":"Computable Publishing LLC"},"system":"urn:ietf:rfc:3986","type":{"text":"FEvIR Object Identifier"},"value":"https://fevir.net/FOI/112103"},{"system":"https://clinicaltrials.gov","use":"official","value":"NCT05503693"},{"assigner":{"display":"Alebund Pharmaceuticals"},"value":"AP303-PK-01"}],"keyword":[{"text":"Safety, Tolerability, Pharmacokinetics, AP303, Healthy Subjects"}],"label":[{"type":{"coding":[{"code":"official","display":"Official title","system":"http://hl7.org/fhir/title-type"}]},"value":"A Single-center Randomized Double-blind Placebo-controlled Study to Investigate the Safety Tolerability and PK of SAD and MAD of AP303 Following Oral Administration and the Effect of Food on the PK of AP303 in Healthy Subjects"}],"name":"NCT05503693_FHIR_Transform","objective":[{"outcomeMeasure":[{"description":"Incidence and severity of adverse events (AEs), laboratory, ECG, and vital sign changes","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-0"},"reference":"EvidenceVariable/112076","type":"EvidenceVariable"},"name":"Single Dose and Food Effect Safety Outcome Measures","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Incidence and severity of AEs, laboratory, ECG, and vital sign changes.","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-1"},"reference":"EvidenceVariable/112077","type":"EvidenceVariable"},"name":"Multiple Dose Safety Outcome Measures","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-2"},"reference":"EvidenceVariable/112078","type":"EvidenceVariable"},"name":"Cmax after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-3"},"reference":"EvidenceVariable/112079","type":"EvidenceVariable"},"name":"Tmax after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-4"},"reference":"EvidenceVariable/112080","type":"EvidenceVariable"},"name":"AUC0-last after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-5"},"reference":"EvidenceVariable/112081","type":"EvidenceVariable"},"name":"AUC0-inf after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-6"},"reference":"EvidenceVariable/112082","type":"EvidenceVariable"},"name":"t1/2 after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-7"},"reference":"EvidenceVariable/112083","type":"EvidenceVariable"},"name":"CL/F after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-8"},"reference":"EvidenceVariable/112084","type":"EvidenceVariable"},"name":"Ae and CLR (if warranted) after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after single dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-9"},"reference":"EvidenceVariable/112085","type":"EvidenceVariable"},"name":"V/F after single dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-10"},"reference":"EvidenceVariable/112086","type":"EvidenceVariable"},"name":"Cmax after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-11"},"reference":"EvidenceVariable/112087","type":"EvidenceVariable"},"name":"Tmax after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-12"},"reference":"EvidenceVariable/112088","type":"EvidenceVariable"},"name":"AUC0-τ after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-13"},"reference":"EvidenceVariable/112089","type":"EvidenceVariable"},"name":"Cav after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-14"},"reference":"EvidenceVariable/112090","type":"EvidenceVariable"},"name":"t1/2 after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-15"},"reference":"EvidenceVariable/112091","type":"EvidenceVariable"},"name":"Rac after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-16"},"reference":"EvidenceVariable/112092","type":"EvidenceVariable"},"name":"Ae and CLR (if warranted) after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-17"},"reference":"EvidenceVariable/112093","type":"EvidenceVariable"},"name":"V/F after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"PK characteristics after multiple dose","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-primaryOutcome-18"},"reference":"EvidenceVariable/112094","type":"EvidenceVariable"},"name":"Ctrough after multiple dose","type":{"coding":[{"code":"primary","display":"Primary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-0"},"reference":"EvidenceVariable/112095","type":"EvidenceVariable"},"name":"Effect of Food on the single dose Cmax","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-1"},"reference":"EvidenceVariable/112096","type":"EvidenceVariable"},"name":"Effect of Food on the single dose Tmax","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-2"},"reference":"EvidenceVariable/112097","type":"EvidenceVariable"},"name":"Effect of Food on the single dose AUC0-last","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-3"},"reference":"EvidenceVariable/112098","type":"EvidenceVariable"},"name":"Effect of Food on the single dose AUC0-inf","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-4"},"reference":"EvidenceVariable/112099","type":"EvidenceVariable"},"name":"Effect of Food on the single dose t1/2","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-5"},"reference":"EvidenceVariable/112100","type":"EvidenceVariable"},"name":"Effect of Food on the single dose CL/F","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-6"},"reference":"EvidenceVariable/112101","type":"EvidenceVariable"},"name":"Effect of Food on the single dose Ae and CLR (if warranted)","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}},{"description":"Effect of food on the single dose PK","endpoint":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693-secondaryOutcome-7"},"reference":"EvidenceVariable/112102","type":"EvidenceVariable"},"name":"Effect of Food on the single dose V/F","type":{"coding":[{"code":"secondary","display":"Secondary","system":"http://terminology.hl7.org/CodeSystem/research-study-objective-type"}]}}]}],"phase":{"coding":[{"code":"SEVCO:01030","display":"Phase 1 trial","system":"https://fevir.net/sevco"}]},"primaryPurposeType":{"coding":[{"code":"treatment","display":"Treatment","system":"http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type"}]},"progressStatus":[{"state":{"coding":[{"code":"completed","display":"Completed","system":"http://hl7.org/fhir/research-study-status"}]}},{"actual":true,"period":{"end":"2023-07-21","start":"2022-12-06"},"state":{"coding":[{"code":"overall-study","display":"Overall study","system":"http://hl7.org/fhir/research-study-status"}]}}],"recruitment":{"actualNumber":62,"eligibility":{"identifier":{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net/FLI","type":{"text":"FEvIR Linking Identifier"},"value":"NCT05503693 Eligibility Criteria"},"reference":"Group/112075","type":"Group"}},"relatesTo":[{"targetUri":"https://clinicaltrials.gov/api/v2/studies/NCT05503693?format=json","type":{"coding":[{"code":"transforms","display":"Transforms","system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type"}]}},{"targetAttachment":{"title":"Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter","url":"https://fevir.net/resources/Project/29885"},"type":{"coding":[{"code":"transformed-with","display":"Transformed With","system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type"}]}}],"resourceType":"ResearchStudy","site":[{"reference":"#NCT05503693-Location-0","type":"Location"}],"status":"active","studyDesign":[{"text":"Design Masking: Quadruple"},{"coding":[{"code":"PARTICIPANT","display":"Participant","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked"},{"code":"SEVCO:01060","display":"Blinding of study participants","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"CARE_PROVIDER","display":"Care Provider","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked"},{"code":"SEVCO:01061","display":"Blinding of intervention providers","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"INVESTIGATOR","display":"Investigator","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked"},{"code":"SEVCO:01063","display":"Blinding of data analysts","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"OUTCOMES_ASSESSOR","display":"Outcomes Assessor","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-WhoMasked"},{"code":"SEVCO:01062","display":"Blinding of outcome assessors","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"RANDOMIZED","display":"Randomized","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-DesignAllocation"},{"code":"SEVCO:01003","display":"randomized assignment","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"SEQUENTIAL","display":"Sequential Assignment","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-InterventionalAssignment"},{"code":"SEVCO:01025","display":"Single-arm crossover design","system":"https://fevir.net/sevco"}]},{"coding":[{"code":"INTERVENTIONAL","display":"Interventional","system":"https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-StudyType"},{"code":"SEVCO:01001","display":"interventional research","system":"https://fevir.net/sevco"}]}],"title":"A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects","url":"https://fevir.net/resources/ResearchStudy/112103"}